SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan ...
For patients presenting with moderate to severe pemphigus, the choice of initial therapy has been distilled to a single agent: rituximab. This drug is more rapidly effective, more likely to provide ...
With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to ...
THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® ...
Rituximab (Rituxan) may be a useful option for children with chronic steroid-dependent Henoch-Schonlein purpura, a small retrospective review suggested. Among eight children with this chronic ...
Risk factors for relapse after reinduction treatment with rituximab in patients with antineutrophil cytoplasmic ...
Imbruvica plus Rituxan significantly improved PFS and response rates in Waldenstrom’s macroglobulinemia patients compared to placebo plus Rituxan. The combination therapy showed a 68% PFS rate at 54 ...
April 20, 2017, Amsterdam, The Netherlands: Results from the RITPBC trial demonstrated that rituximab was not effective for treatment of fatigue in unselected patients with primary biliary cholangitis ...
In comparison with reference rituximab (Rituxan), the use of rituximab biosimilars in combination therapy produced similar 3-year overall survival among patients with large-B-cell lymphoma (DLBCL), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback